[
  {
    "ts": null,
    "headline": "TBLD: Profit From The Market's Shift Towards Europe With This CEF",
    "summary": "Discover Thornburg Income Builder Opportunities Trust with a 7.05% yield, European focus, and discount to NAV. Click to see if TBLD's diversification is for you.",
    "url": "https://finnhub.io/api/news?id=4c3f058de763415545c12e29c82a84e80d15fec6c8a7b8e8dc6e8ce37e4d46c2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743177593,
      "headline": "TBLD: Profit From The Market's Shift Towards Europe With This CEF",
      "id": 133524674,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1440394299/image_1440394299.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover Thornburg Income Builder Opportunities Trust with a 7.05% yield, European focus, and discount to NAV. Click to see if TBLD's diversification is for you.",
      "url": "https://finnhub.io/api/news?id=4c3f058de763415545c12e29c82a84e80d15fec6c8a7b8e8dc6e8ce37e4d46c2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Pflash: A Spotlight on IRA Part D Redesign and its Impact in 2025 Transcript",
    "summary": "REFINITIV STREETEVENTS EDITED TRANSCRIPT PFE.N - Pfizer Inc To Host Pfizer Pflash A Spotlight on IRA Part D Redesign and its Impact in 2025 ...",
    "url": "https://finnhub.io/api/news?id=4c40ff5a66d07716115bfc474a80841f171b6c871f9001f49598952e80971a01",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743176886,
      "headline": "Pfizer Pflash: A Spotlight on IRA Part D Redesign and its Impact in 2025 Transcript",
      "id": 133524564,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "REFINITIV STREETEVENTS EDITED TRANSCRIPT PFE.N - Pfizer Inc To Host Pfizer Pflash A Spotlight on IRA Part D Redesign and its Impact in 2025 ...",
      "url": "https://finnhub.io/api/news?id=4c40ff5a66d07716115bfc474a80841f171b6c871f9001f49598952e80971a01"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Pflash: A Spotlight on IRA Part D Redesign and its Impact in 2025 Presentation",
    "summary": "• $2,000 annual out-of-pocket cap and new Prescription Payment Plan • Sunsetting of the Coverage Gap Discount Program and addition of new...",
    "url": "https://finnhub.io/api/news?id=fb12ff63e21f10621621e2025d7160b3322d78846ae033f18d8d48b3f8863cbc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743160874,
      "headline": "Pfizer Pflash: A Spotlight on IRA Part D Redesign and its Impact in 2025 Presentation",
      "id": 133513269,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "• $2,000 annual out-of-pocket cap and new Prescription Payment Plan • Sunsetting of the Coverage Gap Discount Program and addition of new...",
      "url": "https://finnhub.io/api/news?id=fb12ff63e21f10621621e2025d7160b3322d78846ae033f18d8d48b3f8863cbc"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade)",
    "summary": "Pfizer: $25 support holds strong, with institutional buying signals and growth potential in oncology.",
    "url": "https://finnhub.io/api/news?id=7390a0e182b4c64417d650b5d36846dc4d3c354c5fe04846392c0ca200c277fd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743159992,
      "headline": "Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade)",
      "id": 133513781,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2206288802/image_2206288802.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer: $25 support holds strong, with institutional buying signals and growth potential in oncology.",
      "url": "https://finnhub.io/api/news?id=7390a0e182b4c64417d650b5d36846dc4d3c354c5fe04846392c0ca200c277fd"
    }
  },
  {
    "ts": null,
    "headline": "Transcript : Pfizer Inc. - Special Call",
    "summary": "Presentation Operator MessageOperator Good day, everyone, and welcome to Pfizer Pflash, a spotlight on IRA Part D redesign and its impact in 2025. Today's call is being recorded. \rAt this time, I...",
    "url": "https://finnhub.io/api/news?id=8ad979ee59258f085bd3dc56f6b0550117b16831765687c7e120ab9dec862034",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743156000,
      "headline": "Transcript : Pfizer Inc. - Special Call",
      "id": 134752076,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Presentation Operator MessageOperator Good day, everyone, and welcome to Pfizer Pflash, a spotlight on IRA Part D redesign and its impact in 2025. Today's call is being recorded. \rAt this time, I...",
      "url": "https://finnhub.io/api/news?id=8ad979ee59258f085bd3dc56f6b0550117b16831765687c7e120ab9dec862034"
    }
  },
  {
    "ts": null,
    "headline": "Arbutus Biopharma: A Wing And A Prayer",
    "summary": "Arbutus Biopharma restructures to cut costs & focus on Hepatitis B drug imdusiran. Read more about ABUS stock here.",
    "url": "https://finnhub.io/api/news?id=b89cf27bd8ff89f184da6ba5f55ba77a93466640badb541c4cb08275b0d52b05",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743155311,
      "headline": "Arbutus Biopharma: A Wing And A Prayer",
      "id": 133509757,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184964962/image_184964962.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Arbutus Biopharma restructures to cut costs & focus on Hepatitis B drug imdusiran. Read more about ABUS stock here.",
      "url": "https://finnhub.io/api/news?id=b89cf27bd8ff89f184da6ba5f55ba77a93466640badb541c4cb08275b0d52b05"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
    "summary": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
    "url": "https://finnhub.io/api/news?id=2ec9b46a156413c058393a72e5bee50e867a91233b35571d7b5b27f08d74bd75",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743155082,
      "headline": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
      "id": 133508460,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2ec9b46a156413c058393a72e5bee50e867a91233b35571d7b5b27f08d74bd75"
    }
  },
  {
    "ts": null,
    "headline": "Genmab’s Tivdak approved in Japan for advanced cervical cancer",
    "summary": "The approval is based on open-label Phase III innovaTV 301 clinical trial data.",
    "url": "https://finnhub.io/api/news?id=df89f383c91aa89922a71c6ef11b5084c41c29ff81fad63b31f2517ef0bbd9df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743154483,
      "headline": "Genmab’s Tivdak approved in Japan for advanced cervical cancer",
      "id": 133507784,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The approval is based on open-label Phase III innovaTV 301 clinical trial data.",
      "url": "https://finnhub.io/api/news?id=df89f383c91aa89922a71c6ef11b5084c41c29ff81fad63b31f2517ef0bbd9df"
    }
  },
  {
    "ts": null,
    "headline": "6 Ultra SWANs Potentially Set To Soar In 2025",
    "summary": "A portfolio composed of Ultra SWAN stocks can deliver strong returns for investors. Read about six stock selections that can deliver stable and strong results.",
    "url": "https://finnhub.io/api/news?id=4fcb92cbdb19fe31c8b0ec9effb7b6af12bcc5019b07df56fcd85ac0926bda28",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743145200,
      "headline": "6 Ultra SWANs Potentially Set To Soar In 2025",
      "id": 133507163,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1175286086/image_1175286086.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "A portfolio composed of Ultra SWAN stocks can deliver strong returns for investors. Read about six stock selections that can deliver stable and strong results.",
      "url": "https://finnhub.io/api/news?id=4fcb92cbdb19fe31c8b0ec9effb7b6af12bcc5019b07df56fcd85ac0926bda28"
    }
  }
]